तुलना करने के लिए मीट्रिक्स | 475830 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध475830पीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | 19.7x | −12.9x | −0.3x | |
PEG अनुपात | −0.04 | 0.00 | 0.00 | |
क़ीमत/बुक | 2.0x | 3.3x | 2.6x | |
क़ीमत / एलटीएम बिक्री | 9,011.6x | 11.6x | 2.9x | |
अपसाइड (विश्लेषक लक्ष्य) | - | 60.2% | 67.1% | |
उचित मूल्य अपसाइड | अनलॉक करें | 7.1% | 9.9% | अनलॉक करें |
Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.